An ITC of first-line dual immunotherapy options in advanced melanoma

Dr Iris Dirven, a medical oncologist in training at the University Hospital of Brussels, summarised the main efficacy and safety outcomes of an indirect treatment comparison between first-line nivolumab plus relatlimab versus nivolumab plus ipilimumab in patients with advanced melanoma. She reflected on the relevance of these outcomes for current clinical practice.